טוען...
Clinically relevant GSK-3β inhibitor 9-ING-41 is active as a single agent and in combination with other antitumor therapies in human renal cancer
Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, is involved in a broad range of pathological processes including cancer. GSK-3 has two isoforms, GSK-3α and GSK-3β, and GSK-3β has been recognized as a therapeutic target for the development of new anticancer drugs. The present study aim...
שמור ב:
| הוצא לאור ב: | Int J Mol Med |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
D.A. Spandidos
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6984786/ https://ncbi.nlm.nih.gov/pubmed/31894292 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ijmm.2019.4427 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|